Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

Background Daclizumab is an anti-CD25 monoclonal antibody developed for the treatment of relapsing remitting multiple sclerosis, which was withdrawn worldwide in March 2018, due to emerging serious immune-mediated systemic andcentral nervous system adverse events. We report a case of anti-N-methyl-D...

Full description

Bibliographic Details
Main Authors: Jeremy Chataway, Tarek Yousry, Matthew Walker, Michael S Zandi, Michael P Lunn, Robin S Howard, Jennifer Spillane, Bernadette Monaghan, Kushan Karunaratne, Dariush Ahrabian, Tom Campion, Dimitri M Kullmann
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:BMJ Neurology Open
Online Access:https://neurologyopen.bmj.com/content/3/1/e000096.full

Internet

https://neurologyopen.bmj.com/content/3/1/e000096.full

Similar Items